Amgen Reports Phase 2 Data for Olaparib in Eosinophilic esophagitis

Amgen today announced Phase 2 results for olaparib in patients with eosinophilic esophagitis. The study demonstrated that olaparib reduces biomarker levels compared to standard of care or placebo. These results provide important insights into the treatment of eosinophilic esophagitis and support the continued development of olaparib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.